Denali Therapeutics Shares Gain on Promising Clinical Data

Denali Therapeutics US24823R1059

Investor confidence in Denali Therapeutics is building following the company's presentation of comprehensive clinical updates at the WORLDSymposium in San Diego. The data, highlighting progress across its biotherapeutic transport platform for lysosomal storage diseases, has drawn significant market attention, with a key regulatory milestone now on the horizon for April.

The financial markets responded favorably to the new data package. Last Friday, BTIG reaffirmed its Buy rating on the stock, setting a price target of $32.00. The company's liquidity position, reported at approximately $873 million as of the end of September 2025, provides a substantial runway for continued clinical development. The most immediate catalyst for the stock is set for April 5, 2026. This is the PDUFA date for the U.S. Food and Drug Administration's decision on accelerated approval for tividenofusp alfa. Analysts at Jefferies assign a 70-80% probability to a positive outcome. A successful approval would not only mark a commercial entry for Hunter syndrome but also validate the company's core platform technology for crossing the blood-brain barrier.

Significant Biomarker Reductions in Sanfilippo Syndrome

Updated results from the Phase 1/2 study of drug candidate DNL126 for Sanfilippo syndrome Type A demonstrated substantial reductions in disease-relevant biomarkers. After 49 weeks of treatment, levels of heparan sulfate in the cerebrospinal fluid were reduced by an average of 80%. Furthermore, the biomarker GM3, an indicator of lysosomal function, decreased by 61%.

Notably, three out of seven study participants achieved complete normalization of these biomarker levels at the 49-week mark. The safety profile was in line with expectations and comparable to existing enzyme replacement therapies. These robust data support the company's objective of pursuing an accelerated approval pathway in 2027.

Pipeline Expansion and Platform Validation

Denali is also advancing its broader pipeline. Following the FDA's lifting of a clinical hold in early January, the company has initiated a Phase 1 study for DNL952 in adult patients with Pompe disease. This trial will assess the candidate's safety and pharmacodynamics. Preclinical data suggests DNL952 may reduce glycogen in muscle and brain tissue more effectively than current standard therapies.

For the lead candidate, tividenofusp alfa (for Hunter syndrome), long-term data spanning 201 weeks continues to show promise. Normalization of key biomarkers in both urine and cerebrospinal fluid remained stable throughout this extended period. Clinical parameters, including liver volume and hearing threshold, also demonstrated sustained stability or even improvement, bolstering the case for approval.

@ boerse-global.de | US24823R1059 DENALI